However, the expression levels of CCR2, CCL2, CCL8, and CCL13 in AML cells are not associated with patient prognosis [23,24], suggesting that the involvement of CCR2 and its ligands in AML development may not be clinically relevant. The gene discussed is CCL13; the disease is acute myeloid leukemia.